Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
| Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
|---|---|---|---|---|
| Chen L et al. | 2020 | - | magnetic field, 50/60 Hz | - |
| Chen W et al. | 2023 | <i>Magnaporthe oryzae</i> | magnetic field, 50/60 Hz | - |
| Choi JH et al. | 2022 | intact cell/cell culture, human hair bulb spheroid and hair follicle cultures | magnetic field, 50/60 Hz | - |
| Cios A et al. | 2024 | intact cell/cell culture, HEK293 (kidney cells), 786-O, 769-P and Caki1 (clear cell renal carcinoma cell lines) | magnetic field, 50/60 Hz | - |
| Colciago A et al. | 2021 | intact cell/cell culture, HEI-193 cells (human vestibular schwannoma cell line derived from a NF2 patient) | 50/60 Hz, magnetic field | 0.1 T |
| Consales C et al. | 2018 | intact cell/cell culture, human neuroblastoma cell line (SH-SY5Y) and mouse primary cortical neurons (PCN) | magnetic field, 50/60 Hz | 1 mT |
| Consales C et al. | 2019 | - | magnetic field, 50/60 Hz | - |
| Costantini E et al. | 2019 | intact cell/cell culture, primary human gingival fibroblasts | signals/pulses, magnetic field, 50/60 Hz | 1 mT |
| Cridland NA et al. | 1999 | intact cell/cell culture, HF-19 cells (normal human fibroblasts derived from fetal female lung) | magnetic field, 50/60 Hz | 2 µT–20 mT |
| Czyz J et al. | 2004 | intact cell/cell culture, D3 (murine embryonic stem cell line, p53-deficient and wild type) | magnetic field, 50/60 Hz, power transmission line | 100 µT–2.3 mT |
| D'Angelo C et al. | 2015 | intact cell/cell culture, HaCaT cells (human keratinocytes), SH-SY5Y cells (human neuroblastoma cell line),THP-1 cells (human monocytic leukemia cell line), K562 cells (human erythroleukemic cell line) | magnetic field, 50/60 Hz | 1 mT |
| Dees C et al. | 1996 | intact cell/cell culture, MCF-7 and T-47D cell lines (human breast cancer cell lines) | magnetic field, 50/60 Hz, co-exposure | 1.2–900 µT |
| Dehghani-Soltani S et al. | 2021 | intact cell/cell culture, A172 (human glioblastoma cells) and T98 cell line | magnetic field, 50/60 Hz, signals/pulses, co-exposure, also other exposures without EMF | 7 mT |
| Delle Monache S et al. | 2008 | intact cell/cell culture, human vein endothelial cells (HUVEC) | magnetic field, low frequency, 50/60 Hz | 1 mT |
| Delle Monache S et al. | 2013 | intact cell/cell culture, human umbilical vein endothelial cells (HUVEC) and mouse pancreatic endothelial cell line (MS-1) | magnetic field, low frequency, 50/60 Hz | 1–2 mT |
| Desjobert H et al. | 1995 | intact cell/cell culture, human Epstein-Barr-virus-immortalized lymphoid cells and human leukemic cell line (HL-60) | magnetic field, 50/60 Hz | 10 µT–1 mT |
| Dibirdik I et al. | 1998 | intact cell/cell culture, DT40 (chicken lymphoma B-cells) (wild-type, LYN-deficient, SYK-deficient, PLC-gamma2-deficient clones) | magnetic field, 50/60 Hz | 100 µT |
| Ding GR et al. | 2000 | intact cell/cell culture, MO54 cells (derived from a human malignant glioma) | magnetic field, 50/60 Hz, co-exposure | 5 mT |
| Ding GR et al. | 2001 | intact cell/cell culture, MCF-7 (human breast cancer cell line) | magnetic field, 50/60 Hz, co-exposure | 5 mT |
| Ding GR et al. | 2002 | intact cell/cell culture, MO54 cells (derived from a human malignant glioma) | magnetic field, 50/60 Hz, co-exposure | 5 mT |
| Domínguez G et al. | 2021 | intact cell/cell culture, MDCK cells (Madin-Darby canine kidney cell line) | magnetic field, 50/60 Hz | 1–5 mT |
| Drzewiecka EM et al. | 2021 | isolated organ, tissue slices, fragments of myometrium | magnetic field, 50/60 Hz, low frequency | 8 mT |
| Drzewiecka EM et al. | 2021 | tissue slices | 50/60 Hz, magnetic field | 8 mT |
| Duan Y et al. | 2014 | animal, mouse/ICR, whole body | magnetic field, 50/60 Hz, co-exposure | 8 mT |
| Ebrahimi M et al. | 2019 | mouse/BALB/c | magnetic field, low frequency, 50/60 Hz | - |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.
